# InspireMD, Inc.: financial statements, quarterly NSPR · Nasdaq · CIK 1433607 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/nspr.md) · [Financials](/companies/nspr/financials.md) · [Filings](/companies/nspr/filings.md) · [Insiders](/companies/nspr/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/nspr/financials.md?period=annual). ## Income statement | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [1.6](/filings/0001493152-24-044578.md) | [1.8 d](/filings/0001493152-25-009909.md) | [1.5](/filings/0001641172-25-009250.md) | [1.7](/filings/0001641172-25-022040.md) | [1.8](/filings/0001493152-25-021503.md) | [1.9 d](/filings/0001493152-26-010886.md) | [1.5](/filings/0001493152-26-021636.md) | [1.8](/filings/0001493152-26-038438.md) | [2.5](/filings/0001493152-25-021503.md) | [3.1 d](/filings/0001493152-26-010886.md) | [3.4](/filings/0001493152-26-021636.md) | [1.8](/filings/0001493152-26-038438.md) | | Cost of revenue | $m | [1.1](/filings/0001493152-24-044578.md) | [1.3 d](/filings/0001493152-25-009909.md) | [1.2](/filings/0001641172-25-009250.md) | [1.4](/filings/0001641172-25-022040.md) | [1.4](/filings/0001493152-25-021503.md) | [1.5 d](/filings/0001493152-26-010886.md) | [1.2](/filings/0001493152-26-021636.md) | [1.5](/filings/0001493152-26-038438.md) | [1.7](/filings/0001493152-25-021503.md) | [2.0 d](/filings/0001493152-26-010886.md) | [2.7](/filings/0001493152-26-021636.md) | [2.5](/filings/0001493152-26-038438.md) | | Gross profit | $m | [0.4](/filings/0001493152-24-044578.md) | [0.5 d](/filings/0001493152-25-009909.md) | [0.3](/filings/0001641172-25-009250.md) | [0.3](/filings/0001641172-25-022040.md) | [0.4](/filings/0001493152-25-021503.md) | [0.5 d](/filings/0001493152-26-010886.md) | [0.3](/filings/0001493152-26-021636.md) | [0.3](/filings/0001493152-26-038438.md) | [0.9](/filings/0001493152-25-021503.md) | [1.2 d](/filings/0001493152-26-010886.md) | [0.7](/filings/0001493152-26-021636.md) | [(0.8)](/filings/0001493152-26-038438.md) | | Research and development | $m | [2.1](/filings/0001493152-24-044578.md) | [2.0 d](/filings/0001493152-25-009909.md) | [2.6](/filings/0001641172-25-009250.md) | [3.4](/filings/0001641172-25-022040.md) | [3.9](/filings/0001493152-25-021503.md) | [3.7 d](/filings/0001493152-26-010886.md) | [4.1](/filings/0001493152-26-021636.md) | [3.8](/filings/0001493152-26-038438.md) | [3.6](/filings/0001493152-25-021503.md) | [3.5 d](/filings/0001493152-26-010886.md) | [4.8](/filings/0001493152-26-021636.md) | [4.3](/filings/0001493152-26-038438.md) | | Operating income | $m | [(5.6)](/filings/0001493152-24-044578.md) | [(5.8) d](/filings/0001493152-25-009909.md) | [(7.4)](/filings/0001641172-25-009250.md) | [(8.3)](/filings/0001641172-25-022040.md) | [(8.5)](/filings/0001493152-25-021503.md) | [(9.4) d](/filings/0001493152-26-010886.md) | [(11.5)](/filings/0001493152-26-021636.md) | [(13.0)](/filings/0001493152-26-038438.md) | [(13.1)](/filings/0001493152-25-021503.md) | [(12.1) d](/filings/0001493152-26-010886.md) | [(14.0)](/filings/0001493152-26-021636.md) | [(14.4)](/filings/0001493152-26-038438.md) | | Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net income | $m | [(5.2)](/filings/0001493152-24-044578.md) | [(5.4) d](/filings/0001493152-25-009909.md) | [(7.0)](/filings/0001641172-25-009250.md) | [(7.9)](/filings/0001641172-25-022040.md) | [(7.9)](/filings/0001493152-25-021503.md) | [(9.2) d](/filings/0001493152-26-010886.md) | [(11.2)](/filings/0001493152-26-021636.md) | [(13.2)](/filings/0001493152-26-038438.md) | [(12.7)](/filings/0001493152-25-021503.md) | [(11.8) d](/filings/0001493152-26-010886.md) | [(13.7)](/filings/0001493152-26-021636.md) | [(14.3)](/filings/0001493152-26-038438.md) | | Diluted EPS | $ per share | [(0.15)](/filings/0001493152-24-044578.md) | not reported | [(0.21)](/filings/0001641172-25-009250.md) | [(0.22)](/filings/0001641172-25-022040.md) | [(0.16)](/filings/0001493152-25-021503.md) | not reported | [0.22](/filings/0001493152-26-021636.md) | [(0.26)](/filings/0001493152-26-038438.md) | [(0.17)](/filings/0001493152-25-021503.md) | not reported | [(0.16)](/filings/0001493152-26-021636.md) | [(0.17)](/filings/0001493152-26-038438.md) | | Basic EPS | $ per share | [(0.15)](/filings/0001493152-24-044578.md) | not reported | [(0.21)](/filings/0001641172-25-009250.md) | [(0.22)](/filings/0001641172-25-022040.md) | [(0.16)](/filings/0001493152-25-021503.md) | not reported | [0.22](/filings/0001493152-26-021636.md) | [(0.26)](/filings/0001493152-26-038438.md) | [(0.17)](/filings/0001493152-25-021503.md) | not reported | [(0.16)](/filings/0001493152-26-021636.md) | [(0.17)](/filings/0001493152-26-038438.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfGoodsAndServicesSold - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: not reported - Income tax: not reported - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [13.8](/filings/0001493152-23-039519.md) | [9.6](/filings/0001493152-25-009909.md) | [9.4](/filings/0001493152-24-018889.md) | [28.4](/filings/0001493152-24-030265.md) | [15.8](/filings/0001493152-24-044578.md) | [18.9](/filings/0001493152-26-010886.md) | [12.4](/filings/0001641172-25-009250.md) | [11.5](/filings/0001641172-25-022040.md) | [63.4](/filings/0001493152-25-021503.md) | [8.9](/filings/0001493152-26-038438.md) | [11.4](/filings/0001493152-26-021636.md) | [15.1](/filings/0001493152-26-038438.md) | | Current assets | $m | [46.7](/filings/0001493152-23-039519.md) | [44.2](/filings/0001493152-25-009909.md) | [38.5](/filings/0001493152-24-018889.md) | [51.8](/filings/0001493152-24-030265.md) | [46.4](/filings/0001493152-24-044578.md) | [40.5](/filings/0001493152-26-010886.md) | [32.1](/filings/0001641172-25-009250.md) | [25.5](/filings/0001641172-25-022040.md) | [70.4](/filings/0001493152-25-021503.md) | [61.5](/filings/0001493152-26-038438.md) | [48.6](/filings/0001493152-26-021636.md) | [36.6](/filings/0001493152-26-038438.md) | | Total assets | $m | [50.0](/filings/0001493152-23-039519.md) | [47.6](/filings/0001493152-25-009909.md) | [42.0](/filings/0001493152-24-018889.md) | [55.7](/filings/0001493152-24-030265.md) | [50.5](/filings/0001493152-24-044578.md) | [46.8](/filings/0001493152-26-010886.md) | [38.7](/filings/0001641172-25-009250.md) | [33.3](/filings/0001641172-25-022040.md) | [78.5](/filings/0001493152-25-021503.md) | [69.4](/filings/0001493152-26-038438.md) | [56.5](/filings/0001493152-26-021636.md) | [44.6](/filings/0001493152-26-038438.md) | | Current liabilities | $m | [4.7](/filings/0001493152-23-039519.md) | [6.0](/filings/0001493152-25-009909.md) | [4.9](/filings/0001493152-24-018889.md) | [7.0](/filings/0001493152-24-030265.md) | [7.3](/filings/0001493152-24-044578.md) | [7.7](/filings/0001493152-26-010886.md) | [7.4](/filings/0001641172-25-009250.md) | [9.1](/filings/0001641172-25-022040.md) | [10.8](/filings/0001493152-25-021503.md) | [10.7](/filings/0001493152-26-038438.md) | [9.4](/filings/0001493152-26-021636.md) | [9.6](/filings/0001493152-26-038438.md) | | Total liabilities | $m | [6.8](/filings/0001493152-23-039519.md) | [8.1](/filings/0001493152-25-009909.md) | [6.9](/filings/0001493152-24-018889.md) | [8.9](/filings/0001493152-24-030265.md) | [9.1](/filings/0001493152-24-044578.md) | [10.7](/filings/0001493152-26-010886.md) | [10.3](/filings/0001641172-25-009250.md) | [13.1](/filings/0001641172-25-022040.md) | [14.4](/filings/0001493152-25-021503.md) | [14.2](/filings/0001493152-26-038438.md) | [12.9](/filings/0001493152-26-021636.md) | [13.1](/filings/0001493152-26-038438.md) | | Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Shareholders' equity | $m | [43.3](/filings/0001493152-24-044578.md) | [39.5](/filings/0001493152-26-010886.md) | [35.1](/filings/0001641172-25-022040.md) | [46.8](/filings/0001493152-25-021503.md) | [41.4](/filings/0001493152-25-021503.md) | [36.1](/filings/0001493152-26-038438.md) | [28.3](/filings/0001493152-26-038438.md) | [20.2](/filings/0001493152-26-038438.md) | [64.1](/filings/0001493152-25-021503.md) | [55.2](/filings/0001493152-26-038438.md) | [43.6](/filings/0001493152-26-038438.md) | [31.5](/filings/0001493152-26-038438.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: not reported - Current portion of debt: not reported - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [(4.0) d](/filings/0001493152-24-044578.md) | [(4.2) d](/filings/0001493152-25-009909.md) | [(5.1)](/filings/0001641172-25-009250.md) | [(4.4) d](/filings/0001641172-25-022040.md) | [(5.7) d](/filings/0001493152-25-021503.md) | [(6.8) d](/filings/0001493152-26-010886.md) | [(8.8)](/filings/0001493152-26-021636.md) | [(8.3) d](/filings/0001493152-26-038438.md) | [(8.6) d](/filings/0001493152-25-021503.md) | [(9.3) d](/filings/0001493152-26-010886.md) | [(12.3)](/filings/0001493152-26-021636.md) | [(10.9) d](/filings/0001493152-26-038438.md) | | Capital expenditure | $m | [0.1 d](/filings/0001493152-24-044578.md) | [0.2 d](/filings/0001493152-25-009909.md) | [0.2](/filings/0001641172-25-009250.md) | [0.5 d](/filings/0001641172-25-022040.md) | [0.4 d](/filings/0001493152-25-021503.md) | [0.3 d](/filings/0001493152-26-010886.md) | [0.4](/filings/0001493152-26-021636.md) | [0.6 d](/filings/0001493152-26-038438.md) | [0.3 d](/filings/0001493152-25-021503.md) | [0.4 d](/filings/0001493152-26-010886.md) | [0.2](/filings/0001493152-26-021636.md) | [0.3 d](/filings/0001493152-26-038438.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment ## Shares | Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [7.8](/filings/0001493152-23-039519.md) | [8.1](/filings/0001493152-24-018889.md) | [21.1](/filings/0001493152-24-030265.md) | [34.0](/filings/0001493152-24-044578.md) | [34.2](/filings/0001641172-25-009250.md) | [35.9](/filings/0001641172-25-022040.md) | [48.4](/filings/0001493152-25-021503.md) | [50.0](/filings/0001493152-26-021636.md) | [51.0](/filings/0001493152-26-038438.md) | [73.5](/filings/0001493152-25-021503.md) | [83.8](/filings/0001493152-26-021636.md) | [84.7](/filings/0001493152-26-038438.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 46,489,118 at 2026-08-14, from the cover of the [10-Q filed 2026-08-14](/filings/0001493152-26-038438.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:39 ET. No prices; not investment advice.